X



2013

The strategic objectives Determination and target drug products selection

Establishment of the Arena Life Science: Established in mid-2013 with
just only 4 staff and minimum cash capital



 

2014

 

Establishment of the Arena Life Science:

  • Initiation of R&D phase and selected drug products manufacturing

  • Strengthen the administrative & commercial system

  • Rivaroxaban Entrance to the Drug List



 

2015

 
  • First drug product manufacturing and its entry into the market: The first Iranian manufacturer of anticoagulant drug of Rivaroxaban under the brand name of Axabin.
  • Starting R&D phase of one of the world's most complex recombinant proteins which has been produced only by an American company called Alteplase. Alteplase is the only drug for the treatment of acute ischemic stroke and it is effective in the treatment of acute myocardial infarction as well as pulmonary embolism.
 

2016

 
  • The second drug product manufacturing:
    Production of Sitagliptin under the brand name of Diaptin for the diabetic patient.
  •  
  • The company legal scientific inspection and Arena Life Science selection a as a knowledge-based company
  • The third drug product manufacturing: the first Iranian generic manufacturer of Leflunomide under the band name of Lerava to treat patients with rheumatoid arthritis

2017

Human resources development: Increasing the number of personnel to more than 90 people

The fourth drug product manufacturing: Production of Apixaban under the brand name of Apirax for the first time in Iran

Success in completing the research and development phase of the first recombinant product: Achieving success in registering scientific records and clinical studies documents at the Food and Drug Administration.

 
دی ان ان